Would you recommend starting a moderate-intensity statin in a patient under the age of 40 years old with HIV and a 10-year ASCVD risk estimate below 5%?

I am impressed by the benefit of statins in HIV patients but wonder if the benefit is affected by viral load (which may cause generalized inflammation and/or immune activation).

I have not yet reached the point where I am ready to put low-risk, non-hypercholesteremic HIV patients on statins, but am ...